Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Acquired dysfibrinogenemia has not been previously reported as a paraneoplastic marker for malignancy. This report describes the clinical course of a patient who at the time of diagnosis of nonmetastatic renal cell carcinoma had dysfibrinogenemia characterized by prolongation of the thrombin and Reptilase times and increased sialic acid content of the purified fibrinogen. The thrombin and Reptilase times returned toward normal values after nephrectomy but became abnormal with the development of nonhepatic metastases. It is concluded that acquired dysfibrinogenemia can be part of a paraneoplastic syndrome and is a sensitive plasma marker for tumor progression.
D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000556:secondary / Q000601:surgery; D005260:Female; D005337:Fibrin / Q000032:analysis; D005340:Fibrinogen / Q000378:metabolism*; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid; D009392:Nephrectomy; D010257:Paraneoplastic Syndromes / Q000097:blood*; D012794:Sialic Acids / Q000032:analysis; D013918:Thrombin Time
D012794:Sialic Acids; D005337:Fibrin; D005340:Fibrinogen; D019158:N-Acetylneuraminic Acid